SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Ultragenyx submits European gene therapy application for MPS IIIA

Ultragenyx has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for its investigational gene therapy, rebisufligene etisparvovec, intended for the treatment of MPS IIIA (Sanfilippo Syndrome Type A).

RARE

Related stories